Angus C. Russell - 04 Feb 2025 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role
Director
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Issuer symbol
RVNC
Transactions as of
04 Feb 2025
Net transactions value
-$133,247
Form type
4
Filing time
06 Feb 2025, 15:45:31 UTC
Previous filing
28 Aug 2024
Next filing
25 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Disposition pursuant to a tender of shares in a change of control transaction $133,247 -36,506 -71% $3.65 15,000 04 Feb 2025 Direct F1
transaction RVNC Common Stock Disposed to Issuer -15,000 -100% 0 06 Feb 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Angus C. Russell is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer.
F2 Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price.